News Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Delayed Nasdaq Other stock markets 10:21:53 2024-04-29 am EDT			5-day change	1st Jan Change
0.4952 ^USD	+0.02%		-3.24%	-23.82%

Mar. 25	Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	MT
Mar. 25	Top Premarket Gainers	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data	Mar. 25	MT
Top Premarket Gainers	Mar. 25	MT
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Salarius: Q4 Earnings Snapshot	Mar. 22	AQ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 22	AQ
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	Feb. 22	AQ
Salarius Pharmaceuticals, Inc. Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses	Feb. 22	CI
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders	Jan. 16	AQ
Salarius Pharmaceuticals, Inc. Announces Update on Hematologic Cancer Phase 1/2 Clinical Trial Be Conducted At the University of Texas MD Anderson Cancer Center	Jan. 03	CI
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment	Jan. 03	AQ
Chronic Myelomonocytic Leukaemia Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	Dec. 20	AQ
North American Morning Briefing : Stock Futures -2-	Nov. 16	DJ
Salarius: Q3 Earnings Snapshot	Nov. 10	AQ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	Nov. 07	AQ
Salarius Pharmaceuticals, Inc. Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program	Nov. 07	CI
Salarius: Q2 Earnings Snapshot	23-08-10	AQ
Salarius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Sector Update: Health Care Stocks Decline Thursday	23-08-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Salarius Pharmaceuticals, Inc.

Equities

SLRX

US79400X3052

Summary

Filters